Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics
about
The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode networkPersonality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal studyAcetylcholinesterase and Butyrylcholinesterase Inhibitory Activities of β -Carboline and Quinoline Alkaloids Derivatives from the Plants of Genus PeganumWhen the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor.Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 yearsThe globalization of traditional medicine in northern peru: from shamanism to molecules.Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuascaMethodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine.Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in ratsThe alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro.Methodology for determining major constituents of ayahuasca and their metabolites in blood.Classification and differentiation of the genus Peganum indigenous to China based on chloroplast trnL-F and psbA-trnH sequences and seed coat morphology.4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.Various alkaloid profiles in decoctions of Banisteriopsis caapi.Fast and slow metabolizers of Hoasca.Neuropharmacology of N,N-dimethyltryptamineClinical applications of hallucinogens: A review.Methanol Extract of Croton Pycnanthus Benth. Inhibits Osteoclast Differentiation by Suppressing the MAPK and NF-κB Signaling PathwaysA six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects.Acquired auditory-visual synesthesia: A window to early cross-modal sensory interactions.Bringing ayahuasca to the clinical research laboratory.Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 statusAyahuasca enhances creative divergent thinking while decreasing conventional convergent thinking.A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.Health status of ayahuasca users.Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology.A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions.Behavioral Changes Over Time Following Ayahuasca Exposure in ZebrafishAyahuasca and cancer treatment.Potential Use of Ayahuasca in Grief Therapy.Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies.Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans.The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging.Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities.Syrian rue tea: a recipe for disaster.
P2860
Q21131813-559ABF05-C627-45DE-A144-54185619D67DQ21134103-5025D511-CA95-487C-8E0B-8D74842A3D05Q21284781-F260930C-5EDC-4F0D-8880-4417E391CAE2Q24617727-141286CC-C27D-4151-86FC-178F0CAA7FA3Q26746137-676C576D-9172-47FC-BA18-F9581C2B052BQ26830049-17DA666F-EE14-4803-A856-3D0166A812A5Q28264811-F8B65119-8ECC-4B81-B55C-4F256F2F03C8Q33740814-1B1517A9-8182-4697-82ED-F5BA9062FD67Q33833054-30A0AB69-AA25-4FBB-8050-B3CFE4FAE33CQ33902992-4C303753-1A0C-4337-A611-D279A8C9FED6Q33944518-922F0879-76B0-4B27-A03B-92CAD1B974B3Q34040359-DB198DFF-1E57-40D9-972A-2C29179D4D3AQ34246188-D20BD161-7E38-4370-A2F6-2F4DF88789B7Q34343456-FF067D14-636F-4665-97B5-116BC0551F3CQ34449236-6FB2EEDC-80EA-4BE1-B356-E8EF0E4EBCADQ34449241-5B65BC8A-40DD-4683-B769-C8FB5DD8D4FEQ34524116-CB5120E2-CADC-416E-9A4B-E71D6E0F23E5Q34535259-6ED8A447-0602-4FA3-B533-D50E5BACD4E4Q34627979-D0805B2D-69DE-4F26-979B-7E7CA851731DQ35016895-A0539C27-C680-4F95-8820-D4DD99D05EF9Q35557467-9F8A9704-8805-4FE0-A054-E829F82AD1B6Q36252083-77482B4B-DACF-47DE-89BB-041831DD1377Q36776603-40C1A4BA-4B26-4C71-9CD8-50AA21DB597AQ37184458-C0F34ECB-2A9E-431E-B02E-6A3EB5811B0EQ37988834-4A5113F3-5ABB-41AB-8629-24DDFBA2A881Q38023821-B086B5B3-3C3C-4DD0-B43D-EC4108CB3F7EQ38084557-8E1FE0D0-E5DC-4CD3-AD7A-AE0A52B0C4E1Q38105566-4CCE8EDD-6B6C-4E51-9EAB-FAC3AB0E264CQ38126030-081DCB43-7B3D-422D-993A-C61FF58CA2B0Q38626654-B94A9E5C-0F0C-4AAC-B3C6-7B0A1410F01FQ38697611-FDA20A1C-53C4-429C-81EE-34FA4FC558B3Q38757125-26B8F5CF-F106-4A2C-9C25-DD20041EB19FQ38816768-347E3EA2-D5A0-4994-9675-987A9852A2FDQ38845469-A3B14AC2-69EB-4103-9F89-354505B865DAQ38861685-3684792E-43B7-4CC6-A6D3-C0838E0E0ACDQ39098184-4B71BB8C-8F87-42A7-AE70-0BAD902F5E08Q39146545-DFBE4235-EA2A-43CB-BF56-3A3698A35708Q39548034-A9E23332-B4B3-4043-AE1B-E3AEE975D704Q41595323-9E62F77E-CF1D-40C0-AA6C-8469762E84D8Q42000545-95E1C798-F387-4161-BC43-13B079E620A8
P2860
Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@ast
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@en
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@nl
type
label
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@ast
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@en
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@nl
prefLabel
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@ast
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@en
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@nl
P2093
P921
P3181
P356
P1476
Human pharmacology of ayahuasc ...... xcretion, and pharmacokinetics
@en
P2093
Adelaida Morte
Gloria Urbano
Manel J Barbanoj
Mercedes Yritia
P3181
P356
10.1124/JPET.103.049882
P407
P577
2003-03-26T00:00:00Z